Ibrance 125 MG Oral Tablet

RxCUI: 2284106
RxNorm name: Ibrance 125 MG Oral Tablet
Display name: Ibrance 125 MG Oral Tablet
Full name: Ibrance 125 MG Oral Tablet
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:30

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Ibrance	PALBOCICLIB	U.S. Pharmaceuticals	89a142d5-7e61-48bf-9e77-e2cd124c4792	2026-07-06	Warnings, Adverse reactions	Exact identifier rxcui: 2284106
Ibrance	PALBOCICLIB	Pfizer Laboratories Div Pfizer Inc	fecbdd7d-b729-41b5-9872-231b8fe104ce	2026-07-02	Warnings, Adverse reactions	Exact identifier rxcui: 2284106

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
fecbdd7d-b729-41b5-9872-231b8fe104ce	Ibrance 125 MG Oral Tablet [PSN] · palbociclib 125 MG Oral Tablet [Ibrance] [SBD] · Ibrance 125 MG Oral Tablet [SY]	3	12	These highlights do not include all the information needed to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. IBRANCE ® (palbociclib) tablets, for oral use Initial U.S. Approval: 2015	20260225
89a142d5-7e61-48bf-9e77-e2cd124c4792	Ibrance 125 MG Oral Tablet [PSN] · palbociclib 125 MG Oral Tablet [Ibrance] [SBD] · Ibrance 125 MG Oral Tablet [SY]	3	10	These highlights do not include all the information needed to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. IBRANCE ® (palbociclib) tablets, for oral use Initial U.S. Approval: 2015	20260530